



Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

August 26, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 26, 2021--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The [Personalis NeXT Platform](#)TM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing laboratories globally and is currently the sole sequencing provider to the VA MVP. To enable cancer and population sequencing, The Personalis [Clinical Laboratory](#) is built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ([@PersonalisInc](#)).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210826005028/en/): <https://www.businesswire.com/news/home/20210826005028/en/>

Investor Relations Contact:

Caroline Corner

investors@personalis.com

www.westwickepartners.com

415-202-5678

Media Contact:

Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300

Source: Personalis, Inc.